Table 3. Comparison of baseline characteristics and clinical data from Brussels and Waltz series; all values represent mean ± SD unless otherwise indicated.
| Study authors | Current Study | Waltz et al. | p value |
| Number of patients | 37* | 42 | |
| Age (years) | 13.1±3.3 | 11.7±2.4 | 0.03 |
| Patients treated with HU | 35 (94.6%) | 0 | <0.0001 |
| 6MWD (m) | 551±92 | 491±64 | 0.001 |
| Percentage of predicted distance (%) | 83.2±12.1 | 74.5±10.0 | <0.001 |
| BMI (kg/m2) | 19.1±3.8 | 16.8±2.3 | 0.002 |
| SpO2 (%) | 100 (96–100)** | 97.7±2.5 | NA |
| Hemoglobin (g/dl) | 8.9±1.04 | 8.0±1.3 | 0.001 |
| MCV (fL) | 93.1±10.5 | 79.9±7.7 | <0.0001 |
| Hemoglobin fœtal (% Hb total) | 15±6.3 | 8.2±6.4 | <0.0001 |
* Transfused patients were excluded for this comparison. Only HbSS/Sβ0 phenotypes were compared.
** Values of SpO2 in our series were not gaussian and are expressed in median with range.
HU, Hydroxyurea; 6MWD, 6 minutes walk distance; BMI, Body Mass; SpO2, Arterial Hemoglobin Oxygen Saturation; MCV, Mean Cell Volume; NA, not applicable.